Document:

<PAGE>

                                                                   EXHIBIT 10.73

                                   [SMS LOGO]

February 23, 2001

Mr. John Bruno
Senior Vice President
Cagles, Inc.
2000 Hills Avenue, N.W.
Atlanta, Georgia 30318

RE:  Popeyes' 8-Piece Cost-plus Contract Extension

Dear John:

This letter is to confirm that Cagles and Supply Management Services, Inc. have
agreed to extend the Popeyes 8-Piece Cost-Plus Contract from the current
expiration date of October 4, 2001 to March 31, 2004.  This will coincide with
the expiration date of the Churchs Cost-Plus Agreement.  The letter will be
added as an attachment to the original October 5, 1998 Popeyes Contract.

Thanks for your consideration.

 /s/  Jeff Spotz
----------------------------
Jeff Spotz                              Acknowledged and agreed this 23rd day of
President                               February, 2001

cc:  Dan Cheatham                       Cagles, Inc.

                                        By:  /s/ John Bruno
                                           -------------------------------

                                        Title:  Sr. V.P.
                                              ----------------------------

                          [SMS ADDRESS/TELEPHONE/FAX]<PAGE>

CONFIDENTIAL TREATMENT REQUESTED                                   EXHIBIT 10.19

CONFIDENTIAL TREATMENT REQUESTED: PAGES WHERE CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED ARE MARKED "CONFIDENTIAL TREATMENT REQUESTED" AND APPROPRIATE
SECTIONS, WHERE TEXT HAS BEEN OMITTED, ARE NOTED WITH "[CONFIDENTIAL TREATMENT
REQUESTED]." AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION.

                               OMNIBUS AMENDMENT
                BETWEEN CARDIODYNAMICS INTERNATIONAL CORPORATION
             AND GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC.

     This Omnibus Amendment (this "Omnibus Amendment") is entered into as of
November 22, 2000 (the "Effective Date") by and between CardioDynamics
International Corporation, a California corporation ("CDIC"), and GE Medical
Systems Information Technologies, Inc., a Wisconsin corporation formerly known
as GE Marquette Medical Systems, Inc. ("GEMS-IT"), with reference to the
following facts:

     A.   CDIC and GEMS-IT are parties to that certain Purchase Agreement dated
as of August 25, 1999 (the "Europe Purchase Agreement"), pursuant to which CDIC
agreed to sell BioZ.com Non-Invasive Cardiac Output Monitors and specified
accessories (the "Product") to GEMS-IT for GEMS-IT to promote and distribute in
Europe, the Middle East and Africa.

     B.   CDIC and GEMS-IT are parties to that certain Distribution Agreement
dated as of October 20, 1999 (the "U.S. Distribution Agreement"), pursuant to
which CDIC agreed to sell the Product to GEMS-IT for GEMS-IT to promote and
distribute in the United States including Puerto Rico and dependent territories.

     C.   CDIC and GEMS-IT are parties to that certain Distribution Agreement
dated as of September 19, 2000 (the "Japan Distribution Agreement"), pursuant to
which CDIC agreed to sell the Product to GEMS-IT for GEMS-IT to promote and
distribute in Japan.

     D.   CDIC and GEMS-IT are parties to that certain OEM Development and
Purchase Agreement dated as of July 7, 2000 (the "OEM Agreement"), pursuant to
which CDIC agreed to sell and/or license CDIC ICG Module Kits (as defined in the
OEM Agreement), CDIC sensors, CDIC spare parts and accessories and CDIC software
and related documentation (the "OEM Products") for GEMS-IT to use in connection
with the GEMS-IT ICG Modules (as defined in the OEM Agreement") that GEMS-IT
sells or leases to third parties.

     E.   CDIC and GEMS-IT are parties to that certain Warrant to Purchase
Common Stock of CardioDynamics International Corporation, No. GE-1, dated August
25, 1999 (the "Warrant"), pursuant to which GEMS-IT is entitled, subject to the
terms and conditions thereof, to purchase up to Two Million (2,000,000) shares
of the Common Stock of CDIC (the "Shares"), One Million (1,000,000) of which
such Shares are fully vested.

     F.   The parties hereto desire to: (i) amend the Europe Purchase Agreement,
the U.S. Distribution Agreement, the Japan Distribution Agreement and the OEM
Agreement (collectively, the "Agreements") to the extent necessary to establish
"2001 Minimum Yearly
<PAGE>

Amounts" (as defined below) that GEMS-IT agrees to purchase from CDIC, the value
of which shall be at least $3,500,000 in CDIC's fiscal year 2001; (ii) amend the
Agreements to the extent necessary to establish "2001 Minimum [CONFIDENTIAL
TREATMENT REQUESTED] Amounts" (as defined below) that GEMS-IT agrees to purchase
[CONFIDENTIAL TREATMENT REQUESTED]; (iii) amend the territory definitions
contained in the Agreements so that the foregoing clauses (i) and (ii) amend the
Agreements irrespective of territorial distinctions; (iv ) to confirm the
vesting of the 1,000,000 Shares subject to vesting under subclause (b) of
Section 2.7 of the Warrant; and (v) amend the U.S. Distribution Agreement to the
extent necessary to permit certain additional sales by direct sales
representatives of CDIC.

     NOW, THEREFORE, the parties hereto agree as follows:

     1.   Minimum Yearly Amounts.  The Agreements are hereby amended to
          ----------------------
establish GEMS-IT's firm commitment to purchase at least $3,500,000 of Products
and OEM Products (the "2001 Minimum Yearly Amount").

     2.   Minimum [CONFIDENTIAL TREATMENT REQUESTED] Amounts. The Agreements are
          --------------------------------------------------
hereby amended to establish GEMS-IT's firm commitment to provide purchase
orders, for immediate product delivery, in the following percentages of the 2001
Minimum Yearly Amount during [CONFIDENTIAL TREATMENT REQUESTED] 2001 (the "2001
Minimum [CONFIDENTIAL TREATMENT REQUESTED] Amounts"):

          [CONFIDENTIAL TREATMENT REQUESTED]: by [CONFIDENTIAL TREATMENT
          REQUESTED] GEMS-IT will provide a purchase order for at least
          [CONFIDENTIAL TREATMENT REQUESTED] of the Minimum Yearly Amount;

          [CONFIDENTIAL TREATMENT REQUESTED]: by [CONFIDENTIAL TREATMENT
          REQUESTED] GEMS-IT will provide a purchase order for at least
          [CONFIDENTIAL TREATMENT REQUESTED] of the 2001 Minimum Yearly Amount
          (or a cumulative of [CONFIDENTIAL TREATMENT REQUESTED] of the 2001
          Minimum Yearly Amount);

          [CONFIDENTIAL TREATMENT REQUESTED]: by [CONFIDENTIAL TREATMENT
          REQUESTED] GEMS-IT will provide a purchase order for at least
          [CONFIDENTIAL TREATMENT REQUESTED] of the 2001 Minimum Yearly Amount
          (or a cumulative of [CONFIDENTIAL TREATMENT REQUESTED] of the 2001
          Minimum Yearly Amount); and

          [CONFIDENTIAL TREATMENT REQUESTED]: by [CONFIDENTIAL TREATMENT
          REQUESTED] GEMS-IT will provide a purchase order for at least
          [CONFIDENTIAL TREATMENT REQUESTED] of the 2001 Minimum Yearly Amount
          (or a cumulative of [CONFIDENTIAL TREATMENT REQUESTED] of the 2001
          Minimum Yearly Amount).

     3.   No Territorial Distinctions. The foregoing amendments in Sections 1
          ---------------------------
and 2 above apply irrespective of any minimum purchase commitments by territory
or similar distinctions contained in or implied by the Agreements and supercede
any such distinctions. However,

                                       2
<PAGE>

notwithstanding the foregoing, to the extent any of the Agreements prevent GEMS-
IT from directly or indirectly (a) distributing the Product, (b) soliciting or
accepting orders for the Product, (c) bidding on tenders for the Product or (c)
establishing an office for the purpose of selling and/or servicing the Product
outside any territory defined in any of the Agreements, GEMS-IT remains
obligated to refrain from such activities (e.g., GEMS-IT remains bound by the
                                           ---
terms of Paragraph 4.2 of the Europe Purchase Agreement, Paragraph 2.2 of the
U.S. Distribution Agreement and Paragraph 2.2 of the Japan Distribution
Agreement).

     4.   Placement Commitments. The Agreements are hereby amended to establish
          ---------------------
GEMS-IT's commitment to exercise good faith efforts to place each of the
Products and OEM Products purchased from CDIC into operation at hospitals,
clinics, offices or other third party facilities ("Placement") and not to merely
maintain the Products and OEM Products onsite at GEMS-IT's property. The
Agreements are hereby further amended to establish GEMS-IT's commitment to
exercise good faith efforts to provide evidence of Placement to CDIC, in the
form of a complete list of the names and addresses of all customers of the
Products and OEM Products, the amounts and serial numbers purchased by such
customers, financial statements relating to sales of the Products and OEM
Products and an order and sales forecast for the next quarter within two (2)
weeks of the end of each quarter, or upon request from CDIC.

     5.   Sales by CDIC's Direct Sales Representatives in the United States. The
          -----------------------------------------------------------------
U.S. Distribution Agreement is hereby amended to permit the promotion and sale
by CDIC direct sales representatives of Products to hospitals within the
Territory (as defined in the U.S. Distribution Agreement), irrespective of
whether such hospitals are more than one hundred (100) beds or are within a
corporate partnership of GEMS-IT; provided, however, that such any sales may not
                                  --------  -------
commence until July 1, 2001. Commencing on July 1, 2001, GEMS-IT may elect to
retain its rights as a non-exclusive distributor under the U.S. Agreement or
receive a lead generation fee from CDIC upon such terms and conditions as may be
mutually agreed upon by GEMS-IT and CDIC.

     6.   Warrant Vesting.  The parties acknowledge that upon the execution of
          ---------------
this Omnibus Amendment by both parties, the 1,000,000 Shares referenced in
subclause (b) of Section 2.7 of the Warrant shall vest in accordance with the
terms thereof.

     7.   Termination.
          -----------

     The Agreements may be terminated (i) by CDIC if GEMS-IT fails (A) for
[CONFIDENTIAL TREATMENT REQUESTED] to forward orders for Products and OEM
Products for the applicable 2001 Minimum [CONFIDENTIAL TREATMENT REQUESTED]
Amounts or (B) fails to forward orders for the 2001 Minimum Yearly Amounts, upon
thirty (30) days' prior notice delivered within sixty (60) days following the
end of such [CONFIDENTIAL TREATMENT REQUESTED] or annual period, as the case may
be, or (ii) by either party if the parties fail to agree upon minimum volume
commitments for any CDIC fiscal year by at least [CONFIDENTIAL TREATMENT
REQUESTED] of each year.

     8.   Inconsistency. To the extent that any provision of any of the
          -------------
Agreements or the Warrant is inconsistent with the amendments to such documents
effected by this Omnibus Amendment, each and every such inconsistency, and any
and all related breaches or defaults, are

                                       3
<PAGE>

hereby waived, and any and all claims as a result thereof are hereby released,
by CDIC and GEMS-IT.

     9.   Full Force and Effect.  The Agreements, as amended hereby, remain in
          ---------------------
full force and effect.

     10.  Captions.  The captions in this Omnibus Amendment are for convenience
          --------
only and shall not define or limit any of the terms hereof.

     11.  Counterparts.  This Omnibus Amendment may be executed in multiple
          ------------
counterparts, each of which shall be deemed an original and together shall
constitute one document.

     IN WITNESS WHEREOF, the parties have executed this Omnibus Amendment as
of the Effective Date.

                                       CARDIODYNAMICS INTERNATIONAL
                                       CORPORATION

                                       By:      /s/  Stephen P. Loomis
                                                --------------------------------
                                       Name:    Stephen P. Loomis
                                                --------------------------------
                                       Title:   Chief Financial Officer
                                                --------------------------------

                                       GE MEDICAL SYSTEMS TECHNOLOGIES, INC.

                                       By:      /s/ Kevin M. King
                                                --------------------------------
                                       Name:    Kevin M. King
                                                --------------------------------
                                       Title:   Vice President Clinical Systems
                                                --------------------------------

                                       4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}]]